Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia

Vanderbilt University Medical Center · with National Institute on Drug Abuse (NIDA) · NCT05988710

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
120
US sites recruiting
1
Study start
October 19, 2023
Record last updated
January 12, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this study is to compare the abuse potential of low-dose equianalgesic buccal buprenorphine to a commonly used full mu opioid receptor (MOR) agonist in a highly controlled experimental setting. This is a translational study in which healthy participants are phenotyped for psychosocial and Opioid-Use-Disorder-risk-related metrics. In a within-subjects crossover design, 60 participants will receive a standard postoperative oral oxycodone dose (10 mg), placebo, and 3 different doses of buccal buprenorphine across 5 separate sessions. Quantitative Sensory Testing (QST) will be used to evaluate alterations in pain responsiveness relative to placebo across buprenorphine doses and oxycodone, and will compare abuse potential (indexed by the standard FDA drug liking metric) following equianalgesic doses of the two drugs.

Being studied: Buccal Buprenorphine 300 mcg; Buccal Buprenorphine 600 mcg; Buccal Buprenorphine 900 mcg; Buccal Placebo; Oral Placebo; Oral immediate-release oxycodone 10mg; Buccal Buprenorphine 450mcg

Conditions: Analgesia; Abuse Opioids; Pain

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Intact cognitive status and ability to provide informed consent
  • Ability to read and write in English sufficiently to understand and complete study questionnaires
  • Age 18-65
  • Opioid-naive status (defined as no use of full mu-opioid receptor (MOR) agonist, partial MOR agonist, or mixed agonist/antagonist medications for the prior 3 months by patient report

Exclusion Criteria

  • Liver/kidney disease
  • Chronic pain
  • Current/prior substance use disorder
  • Pregnancy (to avoid fetal drug exposure, with pregnancy tests conducted to confirm eligibility)
  • Seizure disorder
  • Certain psychiatric conditions (severe depression, bipolar disorder, psychotic disorders)
  • Recent use of medications that may interfere with study drug metabolism
  • Recent benzodiazepine or opioid use (confirmed via rapid urine screening prior to each lab session)
  • The presence of any medical conditions felt by the study physician to render participant unsafe
  • Prior allergic reaction or intolerance to oxycodone, buprenorphine, or their analogs (explicitly including moderate-to-severe nausea or vomiting with prior opioids)
  • Recent use of marijuana, delta-8 THC, CBD, and similar products
  • Recent use of kratom
  • Severe asthma
  • Long QT syndrome
  • Parkinson disease
  • Weight \<60 kg

Recruiting US locations

  • Vanderbilt University Medical Center

    Nashville, TN 37069

    Site contact: Daniel Larach Larach, MD, MSTR, MA · 615-322-6033 · daniel.larach@vumc.org

Study contacts (from the official record)

  • Daniel Larach, MD, MSTR, MA · 615-322-6033 · daniel.larach@vumc.org
  • Gail Mayo · 6159361705 · gail.mayo@vumc.org
All healthy volunteers studies in Tennessee →
Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia (NCT05988710) | Bored Studies